Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor ...

Accelerated aging in breast cancer survivors is linked to treatments and tumor characteristics, with implications for ...